Exelixis' Partner Ipsen announces Health Canada's approval of CABOMETYX® (cabozantinib)
Exelixis announced that its partner Ipsen Biopharma received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy. September 19, 2018